Dow Jones component Pfizer (PFE) joined licensing agreements with a number of pharmaceuticals on Friday to launch the biosimilars of AbbVie (megablocker drug) Humira. 19659002] X
In today's afternoon trading on the stock market, the AbbVie share rose 2.4%, close to 92.10. The Pfizer share rose by a fraction near 45.80. The shares traded briefly above a purchase point at 45.91 from a flat base, but the volume remained low. Meanwhile, pharmaceuticals rose by a fraction overall.
Humira is the main drug of AbbVie. It treats various forms of arthritis, psoriasis and Crohn's disease. In 201
"This agreement will facilitate patient access to the (Humira) biosimilar product proposed by Pfizer, which we expect will be an important adjunct to our broad portfolio of biosimilar drugs," said Richard Blackburn, Pfizer's global president Inflammation and Immunology, in a written statement.
Pfizer biosimilar will be late in the US market
Pfizer may launch its Humira biosimilar in November 2023 in the US.  With this, Pfizer lies behind Amgen (AMGN), which can launch in January 2023, and Mylan (MYL), which can launch in July 2023. Among other offerings, Biogen (BIIB) and Novartis (NVS) may launch in June or September of the same year.
Friday's deal resolves all ongoing litigation between Pfizer and AbbVie over a Humira biosimilar.
Several pharmaceutical stocks You have Humira Biosimilars in Europe. Amgen, Biogen and Novartis launched their imitators in October. Biosimilars are nearly identical copies of biological drugs.
Earnings Calendar, Analyst Estimates, and Watchable Stocks
Best Growth Stocks to Buy and Watch: See IBD Stock List Updates
IBD Bearings of the Day